| Literature DB >> 30402118 |
Rui Dong1,2, Jun Ying1,2, Taotao Xu3, Songfeng Hu4, Peng Zhang1,2, Chenjie Xia1,2, Liang Fang1,2, Hongting Jin1,2, Pinger Wang1,2.
Abstract
OBJECTIVE: To investigate the effect and underlying mechanism of Bushenhuoxue (BSHX) formula on articular cartilage repair.Entities:
Year: 2018 PMID: 30402118 PMCID: PMC6196996 DOI: 10.1155/2018/2734581
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The compositions of Bushenhuoxue (BSHX) formula.
| Chinese name | Botanical name | Latin name | Parts used | Proportion |
|---|---|---|---|---|
| Shu Di Huang | Rehmannia glutinosa(Liboscb) | Rehmannia glutinous (Liboscb) | Root | 17.4% |
| Du Zhong | Eucommia ulmoides (Oliv.) | Eucommiae cortex | Bark | 11.8% |
| Fu Zi | Aconitum carmichaeli (Debx.) | Aconitilateralis radix preparata | Root | 11.8% |
| Gou Qi | Lycium barbarum (L.) | Lyciifructus | Fruit | 11.8% |
| Rou Gui | Cinnamomum cassia (Presl) | Cinnamomi cortex | Bark | 5.9% |
| Shan Zhu Yu | Cornus officinalis (Sieb.) | Cornifructus | Fruit | 5.9% |
| Tao Ren | Prunus persica (Batsch.) | Semen Persicae | Fruit | 11.8% |
| Hong Hua | Carthamus tinctorius (L.) | Carthamus tinctorius (L.) | Corolla | 5.9% |
| Shan Yao | Dioscoreae opposite (Thunb.) | Dioscoreae Rhizoma | Root | 11.8% |
| Gan Cao | Glycyrrhiza uralensis (Fisch.) | Glycyrrhizae Radix et Rhizoma | Root | 5.9% |
Primer name and sequences for PCR analysis.
| Primer name | Sequence |
|---|---|
|
| 5′-GGAGATTACTGCCCTGGCTCCTA-3′ |
|
| 5′-GACTCATCTACTCCTGCTTGCTG-3′ |
| Col2a1 forward | 5′-TGGTCCTCT GGGCATCTCAGGC-3′ |
| Col2a1 reverse | 5′-GGTGAACCTGCTGTTGCCCTCA-3′ |
| Mmp13 forward | 5′-TTTGAGAACACGGGGAAGA-3′ |
| Mmp13 reverse | 5′-ACTTTGTTGCCAATTCCAGG-3′ |
| Aggrecan forward | 5′-CGCCACTTTCATGACCGAGA-3′ |
| Aggrecan reverse | 5′-TCATTCAGACCGATCCACTGGTAG-3′ |
| Adamts5 forward | 5′-CCAAATGCACTTCAGCCACGATCA-3′ |
| Adamts5 reverse | 5′-AATGTCAAGTTGCACTGCTGGGTG-3′ |
| Col10a1 forward | 5′-ACCCCAAGGACCTAAAGGAA-3′ |
| Col10a1 reverse | 5′-CCCCAGGATACCCTGTTTTT-3′ |
| Runx2/Cbfa1 forward | 5′-GAGGGCACAAGTTCTATCTGGA-3′ |
| Runx2/Cbfa1 reverse | 5′-GGTGGTCCGCGATGATCTC-3′ |
Figure 1(a) Gross appearance of both model group and BSHX group at 4 and 8 weeks. (b) Assessment of ICRS cartilage repair score. (c) ABH staining for histological sections of both groups. Bar=50μm. (d) Mankin score for cartilage repair. ∗P<0.05, #P<0.01.
Figure 2(a) Immunohistochemistry for Col II in both groups at 4 and 8 weeks, Bar=50μm. (b) IOD/Area ratio of Col2 expression. (c) IHC for Mmp13, Bar=200μm. (d) Positive cell ratio of Mmp13. (e) IHC for Runx2, Bar=200μm. (f) Positive cell ratio of Runx2. ∗P<0.05, #P<0.01.
Figure 3(a) Absorbance values of CCK8 test for cell proliferation and optimal BSHX-mediated serum concentration selection in chondrogenic ATDC5 cells after BSHX formula treatment. The expression alterations in Col2a1 and Aggrecan mRNA (b), Mmp13 and Adamts5 mRNA (c), Col10a1 and Runx2 mRNA (d). ∗P<0.05, #P<0.01.
Figure 4(a) IHC for pSMAD2, Bar=200μm, black arrows point out the positive cells. (b) pSMAD2 positive cell ratio. Transfection efficiency of Tgfβr2 siRNA in Chondrogenic ATDC5 cells. (c) After transfected and BSHX formula treatment, ECM deposition (d), matrix degradation (e), and chondrocytes hypertrophy (f) related gene expression alterations in chondrogenic ATDC5 cells. (g) The protein expression of pSMAD2/3 in chondrogenic ATDC5 cells. ∗P<0.05, #P<0.01.